Veracyte Stock News

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c

Veracyte's revenue grew at a healthy clip in the fourth quarter. The genomic test company's financial health looks solid.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate

Start Time: 16:30 January 1, 0000 5:29 PM ET Veracyte, Inc. (NASDAQ:VCYT ) Q4 2022 Earnings Conference Call February 22, 2023, 16:30 PM ET Company Participants Marc Stapley - CEO Rebecca Chambers - EV

Veracyte (VCYT) delivered earnings and revenue surprises of 66.67% and 6.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market

VIPS, VCYT and EVR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 24, 2023.

As cancer screenings are becoming covered more often, both companies stand to gain.

This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.

Upgrades For Algonquin Power & Utilities Corp (NYSE:AQN), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the third quarter, Algonquin Power showed an EPS of $0.11, compared

Terex and Armstrong World Industries are part of the Zacks Bull and Bear of the Day article.

Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.

Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions relat